[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-breast-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100364843","screening-magnetic-resonance-imaging-of-the-brain-in-patients-with-breast-cancer-100364843",false,"NCT04030507","Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer","Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First\u002FSecond Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed breast cancer with pathologic assessment of estrogen receptor (ER), progesterone receptor (PR), and (human epidermal growth factor receptor 2 (HER2) status. If subtype has changed over the course of a patient's disease, the treating clinician and\u002For study PI is responsible for selecting the subtype that most likely reflects the preponderance of oncologic disease at the time of enrollment.\n* Participants must have radiographic evidence of extracranial, distant metastases or unresectable, locally recurrent breast cancer and be initiating (within 8 weeks of registration) first-line or second-line chemotherapy for their metastatic\u002Frecurrent disease OR inflammatory breast cancer being managed with curative intent within six months of diagnosis.\n* Participants must be age 18 years or older.\n* Participants must have a life expectancy of greater than 12 weeks.\n* Participants must be willing to undergo study procedures.\n* The effects of gadolinium \u002F other magnetic resonance imaging (MRI)-based contrast agents on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n* Participants must possess the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have a contraindication to MRI (e.g. noncompatible implanted metallic device for which MRI is absolutely contraindicated).\n* Participants who have chronic kidney disease stage IV-V or end stage renal disease.\n* Participants with a history of anaphylactic reactions to gadolinium.\n* Pregnant women are excluded from this study because gadolinium-based agents have not been proven to be safe to administer to a developing fetus. Similarly, breastfeeding women will be excluded from this study.\n* Patients with a prior diagnosis of brain metastases","ALL","18 Years",{"count":19,"type":20},214,"ESTIMATED","INTERVENTIONAL",[23],"NA","This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).",[26,27,28,29,30,31],"Breast Cancer","HER2-positive Breast Cancer","Triple Negative Breast Cancer","Hormone Receptor Positive Malignant Neoplasm of Breast","Inflammatory Breast Cancer","Metastatic Breast Cancer",[26,27,28,29,30,33],"Metastatic breast cancer","RECRUITING","2026-03-17",{"date":37,"type":38},"2026-03-19","ACTUAL",{"date":40,"type":38},"2019-07-26",{"date":42,"type":20},"2028-02",{"name":44,"class":45},"Brigham and Women's Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100411375","refining-local-regional-therapy-for-ibc-100411375","NCT04636710","Refining Local-Regional Therapy for IBC","Refining Local-Regional Therapy for Inflammatory Breast Cancer (IBC)","Inclusion Criteria:\n\n* Stage III IBC (cT4d cN0-2). Inflammatory breast cancer is defined as the following constellation of symptoms (all of the following must be met):\n\n  * Rapid onset symptoms (6 months or less from time of diagnosis)\n  * Breast erythema, edema and\u002For peau d'orange and\u002For warm breast with or without an underlying palpable mass\n  * Erythema occupying at least one-third of the breast\n  * Pathologic confirmation (biopsy-proven) invasive breast carcinoma\n* Women age ≥18 years\n* ECOG performance status ≤2\n* Ability to understand and willingness to sign informed consent document and comply with study procedures, including baseline research biopsy. If the research biopsy is not felt to be reasonably safe or feasible, a waiver must be obtained from the Principal Investigator. A formal exception would not be required in this case.\n\nExclusion Criteria:\n\n* Participants who initiated pre-operative\u002Fneoadjuvant therapy prior to registration are ineligible.\n* Participants with Stage IV (metastatic) breast cancer are excluded. The absence of any evidence of distant disease on staging studies needs to be confirmed at the time of diagnosis (within 42 days from initial presentation) using the staging studies that are standard for the participating institution.\n* Participants with positive contralateral axillary nodes identified on standard imaging studies (MMG, MRI, US) are excluded. In participants with clinically suspicious axillary nodes, US guided biopsy will be performed prior to registration. If the contralateral axillary biopsy is positive, patients will not be eligible. If standard imaging does not identify contralateral disease yet drainage to the contralateral axillary basin is identified on pre-NAC lymphoscintigraphy, contralateral axillary US (if not already performed) will be obtained and any suspicious contralateral axillary nodes will undergo US guided biopsy. If the contralateral axillary biopsy is positive, patients will not continue on study for the evaluation of the primary endpoint, but their data will be used for the descriptive analyses of lymphatic drainage patterns in IBC. Contralateral invasive breast cancer without axillary involvement or in-situ carcinoma in either breast is allowed.","FEMALE",{"count":56,"type":20},50,[23],"This Feasibility study is trying to determine:\n\n* If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer.\n* The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy.\n* The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory breast cancer\n* Outcomes for women with inflammatory breast cancer, whether or not the sentinel lymph nodes can be identified.",[26,30,60],"Sentinel Lymph Node",[26,30,60],"2025-12-22",{"date":64,"type":38},"2025-12-29",{"date":66,"type":38},"2021-06-02",{"date":68,"type":20},"2028-12-01",{"name":70,"class":45},"Dana-Farber Cancer Institute",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":54,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100526199","conserving-surgery-in-inflammatory-breast-cancer-after-neoadjuvant-chemotherapy-100526199","NCT06131632","Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy","Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy in Patients With Clinical Complete Response (ConSIBreC): a Randomized Clinical Trial","ConSIBreC","Inclusion Criteria:\n\n* Patients with inflammatory breast cancer\n* Clinical complete response after neoadjuvant chemiotherapy\n* Targeted tumor\n* Written informed consent\n\nExclusion Criteria:\n\n* Metastasis\n* Progression disease\n* Recurrent disease\n* Contraindications to adjuvant radiation therapy",true,"70 Years",{"count":82,"type":20},300,[23],"Inflammatory breast cancer is an aggressive and rare form of breast cancer, which accounts for 2-3% of all breast cancers. The classic presentation of inflammatory breast cancer includes erythema, edema, and peau d'orange of at least one\u002Fthird of the breast.\n\nCurrent treatment of inflammatory breast cancer include: neoadjuvant chemiotherapy, modified radical mastectomy and radiation therapy.\n\nIn the last two decades the development of new targeted therapies has significantly improved the efficacy of neoadjuvant chemiotherapy allowing a de-escalation of surgical treatment in patients with non-inflammatory breast cancer that achieve clinical complete response.\n\nThere are few retrospective studies that evaluate implications of surgical treatment on survival among these patients. This may justify trial aims to investigate the possible use of the breast conserving surgery in patients with inflammatory breast cancer that achieve clinical complete response after neoadjuvant chemiotherapy.",[30],[87,88,89],"inflammatory breast cancer","breast conserving surgery","radical mastectomy","NOT_YET_RECRUITING","2024-01-22",{"date":93,"type":38},"2024-01-23",{"date":95,"type":20},"2024-03-01",{"date":97,"type":20},"2028-01-01",{"name":99,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]